German biotech company bitop AG announced that it has begun enrolling patients in a clinical trial of its Ectoin inhalation solution for the treatment of airway inflammation. In addition to the inhalation solution, bitop is also developing an Ectoin nasal spray and and a DPI. According to bitop, Ectoin is a naturally-occurring "cell protection molecule." Read the company’s press release.
